Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 170

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 170
---
 became the Company’s
Chief Financial Officer. effective as of June I, 2023. He has over 13 years of experience in accounting, auditing and finance of Hi-Tech
and biotechnology companies. Since 2018, he serves as Head of IPO & M&A Department at Shimony Financial Services (Israel) and
has been providing accounting and financial advisory services to the Company since 2018. He knows company’s history, prepared all
quarterly and annual reports, experienced in RCC and PCAOB reporting. Before joining Shimony CPA FIRM, from 2009 to 2017, Mr. Gordashnikov
was an Audit Manager at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management,
a B.A. in Accounting and Economics from Hebrew University of Jerusalem and he has been a licensed CPA since 2012.

<div align='center'>106</div>

Bernard Bartal, 59, joined the Company
as a director in June 2023 and, since June 22, 2023, has served as Chairman and Vice President of Business Development,. Throughout his
career, Mr. Bartal has been a founder, co-founder, investor, and strategic technology contributor to numerous life science and technology
ventures.

He has played leading roles in a range of
companies, including Dien-A Molecular Biology Ltd. (2018–present), a DNA sequencing company pioneering technologies for
significantly extending sequencing read lengths; Advanced Concepts in Biology LLC (2018–present), which develops advanced gene
expression technologies; and Biotic Therapeutics Ltd. (2021–2023), where he also served as Vice President of Business
Development, focusing on anti-inflammatory polyphenol small molecule research. Between 2018 and 2020, he was a shareholder and
contributor to Aimmune Therapeutics, a company developing peanut allergy therapeutics that was acquired
by Nestlé in 2020. Since March 2023 to the present, he has been serving as a board member and technology
adviser at Exonavis Therapeutics, which is currently in Phase III clinical development for ADNP, and since 2024 has been an advisory
board member, first shareholder, and strategy contributor at Listen Therapeutics, a company advancing breakthrough real-time cancer
treatment efficacy signaling technology. In the agri-biotech field, he founded Agrinetica and Agronetica (April 2023–present),